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therosclerosis, the major cause of death in industrialized societies, is initiated by the retention in arteries of cholesterol-enriched, apoB-containing lipoproteins and their subsequent uptake by arterial wall macrophages, giving rise to macrophage foam cells. 1 HDL and HDL apolipoproteins protect against the development of atherosclerosis, probably primarily by stimulating the efflux of cholesterol from macrophage foam cells. 2, 3 A breakthrough in this area of research
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has been the elucidation of mutations in the ATP-binding cassette transporter A1 (ABCA1) 4 -6 as the genetic defect in Tangier disease, a disorder characterized by HDL deficiency, defective apolipoprotein-mediated phospholipid and cholesterol efflux from cells, and the accumulation of macrophage foam cells in various tissues, including arteries. The pheno-typic defects of Tangier disease are consistent with the proposed function of ABCA1 as a cell surface transporter that promotes the efflux of cellular phospholipids and cholesterol to lipid-poor apolipoproteins, a process that constitutes the initial step in HDL formation. 7, 8 The finding that ABCA1 mutations cause Tangier disease has stimulated studies of ABCA1 functions in vivo and in vitro. As reviewed elsewhere in this series, these studies confirm the pivotal role of ABCA1 in HDL formation and indicate an antiatherogenic role of ABCA1, especially ABCA1 in the macrophage. 9 -11 Studies of the regulation of ABCA1 gene expression have revealed that ABCA1 is induced in cholesterol-loaded cells as a result of activation of LXR/RXR heterodimer and induction of ABCA1 expression is probably central to the antiatherogenic effects of LXR ligands in vivo. [12] [13] [14] This review will focus on the regulation and function of ABCA1, emphasizing recent work on the apolipoprotein-mediated post-transcriptional regulation of ABCA1 turnover and function.
Role of Apolipoprotein Binding to ABCA1 in the Regulation of Lipid Efflux
ABCA1 is a large membrane protein with 2 transmembrane domains and 2 nucleotide-binding folds linked by an intracellular peptide segment ( Figure 1 ). After translation, ABCA1 is further processed by glycosylation and presented at the cell surface. 15 The primary function of ABCA1 is to promote cellular cholesterol and phospholipid efflux, which requires the presence of extracellular lipid-poor apolipoproteins. 16, 17 However, the detailed molecular events linking apolipoproteins to ABCA1-facilitated cellular lipid efflux are still not clear. Before the discovery of ABCA1, a number of different laboratories had demonstrated apolipoproteinmediated phospholipids and cholesterol efflux from cells, 18 -20 and Francis et al 21 discovered that this process was defective in Tangier disease fibroblasts. Subsequent to the discovery that ABCA1 mutations cause Tangier disease, we and others found that transfection of the full-length cDNA of ABCA1 in cells resulted in increased apoA-I binding to the cell surface. 17, 22 These studies also showed that apoA-I could be chemically cross-linked to ABCA1, suggesting close proximity of apoA-I to ABCA1 (ie, within about 11 Å). 17 These findings led us to suggest that apoA-I directly binds ABCA1 to form a complex that is required for ABCA1-facilitated cellular cholesterol and phospholipid efflux. 17 In contrast to this idea, Chambenoit et al 23 proposed that apoA-I binding might not involve a direct molecular interaction between ABCA1 and apoA-I but rather a modified distribution of plasma membrane lipids induced by ABCA1 expression, leading to "docking" of apoA-I molecules at the cell surface, perhaps in close proximity to ABCA1. The authors provided 3 lines of evidence to support this hypothesis. First, apoA-I binding requires functional ABCA1 because an ABCA1 mutant with defective ATPase activity fails to bind apoA-I. Second, ABCA1 expression at the cell surface is not linearly correlated with apoA-I binding, as determined by fluorescence quantification of apoA-I binding and cell surface ABCA1 protein levels. Third, the lateral mobility of ABCA1 green fluorescent protein in membranes appears to be different from that of membrane-bound apoA-I. 23 The authors suggested that apoA-I is likely bound to phosphatidylserine (PS) that is presented to the exofacial leaflet by the "floppase" activity of ABCA1 because PS levels on the exofacial leaflet are increased by ABCA1 expression. 23 However, Smith et al 24 reported that although ABCA1 expression increased PS levels on the exofacial leaflet, the increased PS was insufficient to mediate cellular apoA-I binding and lipid efflux because annexin V, a PS-binding protein, did not compete with ABCA1-induced apoA-I binding, nor did it affect ABCA1-mediated lipid efflux to apoA-I. 24, 25 Using a fluorescence photobleaching technique, this study also suggested that apoA-I bound to an integral membrane protein in ABCA1-expressing cells. 24 The controversy about apoA-I/ABCA1 interaction has also been looked into from a different angle using apoA-I mutants. 26 The C-terminal lipid-binding helix 10 of apoA-I was identified to be critical for apoA-I-mediated cholesterol efflux from ABCA-expressing cells, 26 and a positive correlation between cholesterol efflux and the lipid-binding characteristics of apoA-I was observed. 26 These findings led to a composite model to explain the interaction between apoA-I and ABCA1, that is, helix 10 of apoA-I tethers the lipid-free apolipoprotein to the ABCA1-generated lipid domain that then diffuses within the plane of the membrane until it comes in contact with ABCA1, where a protein-protein interaction could lead to the lipidation of apoA-I. 26 However, the data do not distinguish whether apoA-I/lipid binding precedes the interaction of apoA-I with ABCA1 or the other way around.
The ABCA1 molecule has 2 large extracellular loops, probably linked by a disulfide bond, located on each of the 2 transmembrane domains (Figure 1 and 27,28 ). Importantly, many ABCA1 missense mutations causing Tangier disease have been identified in these loops. 29 A functional test of these mutations in transfected cells revealed defects in apoA-I binding and cellular lipid efflux. 27, 28 Interestingly, one of the mutants, W590S, showed lipid efflux deficiency but moder- Figure 1 . ApoA-I-mediated stabilization of ABCA1 by inhibiting PEST-dependent calpain proteolysis. ApoA-I binds to ABCA1 and causes inhibition of calpain-catalyzed proteolysis of ABCA1 by promoting cellular phospholipid efflux or by inducing a conformational change of ABCA1 that inhibits access of calpain to the PEST sequence. Calpeptin is a specific inhibitor of calpain and increases ABCA1 protein by reducing calpain proteolysis.
ately increased apoA-I binding. 27 These findings have been confirmed independently 30, 31 and strongly suggested that apoA-I directly binds ABCA1 at the cell surface without requiring the ability of ABCA1 to mediate lipid efflux. Together, these results also suggest that apoA-I binding requires an ABCA1 molecule assuming an optimal structural conformation that is maintained by a functional ATPase because cell-surface ABCA1 mutants with defective ATPase fail to bind apoA-I. 23, 32 The moderate increase in apoA-I binding to W590S may imply that dissociation of apoA-I from ABCA1 could be facilitated by lipid efflux to apolipoproteins bound to ABCA1 and is consistent with the earlier finding that ABCA1 binds apoA-I but not HDL 3 . 7 Extrahepatic ABCA1 functions to promote cholesterol efflux from peripheral tissues to lipid-poor apolipoproteins that in turn deliver the lipid load back to liver for disposal, a process likely involving scavenger receptor BI, which has high affinity for lipid-rich HDLs but low affinity for lipidpoor apolipoproteins. 33 Hepatic ABCA1 is likely involved in pre-␤ HDL formation in liver, demonstrated by increased pre-␤ HDL as well as more mature HDL levels in mice with adenovirus-mediated expression of ABCA1. 34 Like scavenger receptor BI, ABCA1 binds not only apoA-I but also other apolipoproteins, including apoE. 35 Thus, the antiatherogenic effect of apoE in vivo could be partially explained by lipid efflux from macrophage foam cells coordinated with ABCA1.
Apolipoprotein Binding in the Regulation of ABCA1 Turnover
Cellular expression of ABCA1 is highly regulated. As a consequence of increased ABCA1 expression, apolipoprotein-mediated cellular cholesterol efflux is also enhanced, 17, 22 leading to a decreased cellular cholesterol accumulation. Highly regulated ABCA1 expression may reflect the necessity to tightly regulate ABCA1 protein levels by the cell to maintain cellular cholesterol and phospholipid homeostasis. During cholesterol loading of macrophages, cellular cholesterol and phospholipid content are increased, the latter is caused by increased phospholipid synthesis 36 and is a protective response against cytotoxicity caused by cholesterol accumulation. 37 Therefore, induction of ABCA1 expression could help the cell shed excess cholesterol and phospholipids and reach a new steady state of cellular lipid metabolism. However, overexpressed ABCA1 in the absence of cholesterol loading causes an altered membrane structure, 7 which could be detrimental to the cell. Oram et al 22 showed that the turnover of ABCA1 protein was rapid with a short half life less than 1 hour in murine macrophage-like cells. Thus, the induction of ABCA1 expression by cholesterol loading and rapid turnover of ABCA1 protein suggest the existence of cellular mechanisms tightly regulating the protein levels of ABCA1 to maintain lipid homeostasis. The cellular processes regulating the turnover of ABCA1 protein have only recently received attention. ABCA1 is present at the cell surface and proposed to function primarily at plasma membranes. 32 However, intracellular localizations of ABCA1 have been observed, 38, 39 and ABCA1-mediated lipid efflux may involve intracellular lipid trafficking 38, 39 or apoA-I endocytotic recycling. 40 Using ABCA1 green fluorescent protein fusion protein and confocal and time-lapse fluorescence microscopy, Neufeld et al 39 found that ABCA1 is on the cell surface and in intracellular vesicles, including early endosomes, late endosomes, and lysosomes. They have suggested that delivery of ABCA1 to lysosomes could be a mechanism to regulate ABCA1 protein turnover and to modulate its cell surface expression and function. 39 A key role of late endosomes/lysosomes in providing cholesterol for ABCA1-mediated efflux is indicated by the severe defect in apolipoprotein-mediated cholesterol efflux in Niemann-Pick C macrophages. 41 Regulation of protein turnover of membrane receptors by their ligands has been reported. 42 Because apoA-I directly binds ABCA1, we speculated that apoA-I might regulate ABCA1 protein turnover. Indeed, we found that apoA-I binding increased ABCA1 protein levels in mouse primary hepatocytes, peritoneal macrophages, and transfected cells without affecting ABCA1 mRNA levels. 31 We also showed that apoE had a similar positive effect on ABCA1 protein levels. 31 Arakawa and Yokoyama 43 independently reported that apoA-I increased ABCA1 protein in human THP-1 cells. Furthermore, they demonstrated that the positive effect of apoA-I on ABCA1 was likely mediated by inhibiting ABCA1 degradation by an unknown thiol protease. 43 We obtained similar results showing that nonspecific thiol protease inhibitors increased ABCA1 protein levels in transfected 293 cells. 31 Many short-lived proteins have specific peptide motifs that target proteins for rapid degradation. One of the motifs is PEST, which is defined as a peptide sequence enriched in proline (P), glutamate (E), serine (S), and threonine (T), and usually flanked by lysine (K), arginine (R), or histidine (H) residues. 44 Using the program PESTfind, we identified a conserved potential PEST sequence in ABCA1 (Figure 1 ). This PEST sequence appeared to be important in regulation of ABCA1 function because PEST deletion resulted in a 4-to 5-fold increase in cell surface ABCA1 protein and significantly increased ABCA1-mediated lipid efflux and apoA-I binding. 31 PEST sequences often increase protein turnover by enhancing protein ubiquitination and proteasomal degradation. 44 In contrast with the lack of effect of lactacystin, a specific inhibitor of proteasome, on ABCA1 protein levels in THP-1 cells as reported by Arakawa and Yokoyama, 43 ABCA1 was ubiquitinated in 293 cells, and lactacystin moderately increased ABCA1 protein levels in both 293 cells and mouse peritoneal macrophages, 31 suggesting that the proteasomal degradation pathway is involved in ABCA1 turnover. Additional evidence supporting the involvement of the proteasomal pathway in ABCA1 turnover came from another study showing that free cholesterol accumulation in mouse peritoneal macrophages resulted in reduced ABCA1 protein levels that could be reversed by lactacystin treatment. 45 However, we found that the PEST deletion ABCA1 mutant was still ubiquitinated and the protein level of the mutant was also increased by lactacystin treatment, 31 suggesting that ubiquitination and proteasomal degradation of ABCA1 is not controlled by the PEST sequence. In a few instances, PEST sequences have been implicated in proteol-ysis of the target proteins by calpains, a subfamily of thiol proteases. 46 Indeed, a specific calpain protease inhibitor, calpeptin, substantially increased total and cell surface wildtype ABCA1 levels but had no effect on the protein level of the PEST deletion mutant, 31 suggesting that ABCA1 is a target of calpain proteolysis and that the PEST sequence helps to target calpain to cell-surface ABCA1. Further, purified -calpain protease added to permeabilized cells efficiently degraded wild-type ABCA1 but not the PEST deletion mutant, providing direct evidence that PESTdependent degradation of ABCA1 is mediated by calpain protease. 31 Calpeptin treatment also increased ABCA1 protein levels in primary mouse hepatocytes and mouse peritoneal macrophages, 31 suggesting a physiological role of calpain protease in regulation of ABCA1 turnover.
Because apoA-I binding increased ABCA1 protein levels, we then tested whether apoA-I-mediated ABCA1 stabilization was mediated by inhibiting calpain proteolysis in a PEST sequence-dependent fashion. ApoA-I increased levels of wild-type ABCA1 but not of the PEST deletion mutant, and apoA-I pretreatment blocked the degradation of the wild-type ABCA1 by purified calpain protease added to the permeabilized cells. 31 Together, these results have provided convincing evidence for a novel mode of regulation of ABCA1: apoA-I stabilizes ABCA1 by inhibiting PEST sequencemediated calpain proteolysis. To evaluate the effect of apoA-I on ABCA1 as a potential mechanism for its anti-atherogenic role in vivo, we injected a bolus of apoA-I into mice and determined ABCA1 protein levels. Intravenous apoA-I injection resulted in an induction of ABCA1 protein in liver and peritoneal macrophages. 31 However, hepatic and macrophage ABCA1 protein levels showed no change in apoA-I knockout or transgenic mice, 31 suggesting that some form of chronic adaptation may occur as a result of sustained alterations in apoA-I levels. Therefore, these studies may provide a potential explanation for previously observed antiatherogenic effects of apoA-I infusion, that occurred even without sustained elevation of HDL levels, and suggest a rationale for apoA-I infusion trials in humans. 47 Our findings also suggest that intermittent dosing with apoA-I could be more effective than sustained overexpression in upregulating ABCA1 and cellular cholesterol efflux.
To further explore the mechanism for apoA-I-mediated ABCA1 stabilization, we used several ABCA1 mutants with defective transporter functions. ApoA-I failed to increase protein levels of an ATP-binding motif mutant that had been shown to be defective in both apoA-I binding and apoA-I mediated lipid efflux, 32 indicating that apoA-I binding to ABCA1 is likely necessary for apoA-I-mediated ABCA1 stabilization. Binding of apoA-I to ABCA1 leads to cellular cholesterol and phospholipid efflux. It may also cause conformational changes of ABCA1, as reported for ligandinduced conformational changes of other ABC transporters. 48 Cholesterol efflux appears to have no effect on ABCA1 protein levels because HDL and cyclodextrin treatment promoted cholesterol efflux to an extent similar to or greater than that by apoA-I-mediated cholesterol efflux but failed to alter ABCA1 protein levels. 31 Another mutation of ABCA1 that causes Tangier disease (W590S) has been shown to cause a moderate increase in apoA-I binding but defective lipid efflux. 27 ApoA-I failed to increase ABCA1-W590S levels whereas calpeptin significantly increased ABCA1-W590S proteins, suggesting that apoA-I binding is not sufficient for ABCA1 stabilization. 31 These results favor the hypothesis that apoA-I-mediated ABCA1 stabilization may result from a local change in membrane phospholipids that decreases the binding of a hydrophobic, glycine-rich sequence of the small calpain subunit. 49 However, an equally valid interpretation is that apoA-I fails to bind the W590S mutant in the correct orientation and therefore the appropriate conformational change of ABCA1 required to decrease calpain proteolysis does not occur. Calpain proteolysis is also regulated by other cellular processes, such as protein phosphorylation. 46 Phosphorylation of the target protein often increases its degradation by calpain protease. 50 Martinez et al have obtained preliminary results showing that ABCA1 is phosphorylated in the PEST sequence and that apoA-I decreases ABCA1 phosphorylation (Martinez LO, Wang N, Tall AR. Unpublished observation). Therefore, it is likely that apoA-I binds ABCA1, promotes lipid efflux, and causes a conformational change of ABCA1. These changes are accompanied by decreased ABCA1 PEST sequence phosphorylation and decreased ABCA1 degradation by calpain.
The finding that ABCA1 is ubiquitinated 31 and degraded by the proteasome pathway 31, 45 likely reflects an independent mechanism in the regulation of ABCA1 turnover. The cellular compartment in which ABCA1 ubiquitination occurs is unknown and endoplasmic reticulum or plasma membrane could both be potential sites. Although marked free cholesterol accumulation in macrophages leads to ABCA1 degradation, which is reversed by inhibition of proteasome pathway, 45 the physiological significance of this pathway in regulation of ABCA1 turnover in vivo is still not clear. Interestingly, the cystic fibrosis transporter regulator (CFTR), another ABC transporter, has also been shown to be ubiquitinated and degraded by the proteasome pathway. 51 Conformational maturation of wild-type CFTR in the endoplasmic reticulum is an inefficient process, where approximately 75% of newly synthesized CFTR molecules are degraded by cytoplasmic proteasomes shortly after synthesis. 52 Defective protein folding of some CFTR mutants has been proposed as the cause for cystic fibrosis, and great efforts have been made to explore different mechanisms to help the folding of the mutant CFTR. 52 Similarly, a recent study suggests that some ABCA1 missense mutations leading to Tangier disease also show defective ABCA1 presentation at the cell surface, 28 perhaps reflecting defective protein folding.
Regulation of ABCA1 Protein Turnover as a Result of Altered Lipid Metabolism
In addition to apolipoproteins, ABCA1 turnover is also modulated by changes of cellular lipid metabolism. Wang and Oram 53 reported that unsaturated fatty acid accelerate the degradation of ABCA1 without altering ABCA1 mRNA levels and thus decreases apoA-I-mediated lipid efflux, although the specific proteolytic pathway is not known. Because type 2 diabetes and insulin resistance are characterized by elevated fatty acids, low plasma HDL levels, and increased risk of cardiovascular diseases, impaired ABCA1-mediated cholesterol efflux from macrophages may contribute to the enhanced atherosclerosis associated with these metabolic disorders. 53 Indeed, Uehara et al 54 reported that hepatic and macrophage ABCA1 expression were markedly decreased in diabetic mice and this was reversed by insulin treatment. Furthermore, they also showed that ABCA1 mRNA and protein levels were reduced by unsaturated, but not saturated, fatty acids in hepatoma and macrophage-like cell lines. 54
Mechanisms of ABCA1-Mediated Lipid Efflux
The molecular mechanism for ABCA1-mediated lipid efflux is still poorly understood, and several models have been proposed. Some studies have suggested that ABCA1 is localized in and promotes lipid efflux from a membrane lipid domain distinct from cholesterol-and sphingomyelin-rich rafts. 55 Several other studies have suggested the opposite interpretation 56 or suggested that both raft and nonraft domains contribute to ABCA1-facilitated lipid efflux to apoA-I depending on the cell types. 57 Phospholipid and cholesterol efflux promoted by ABCA1 can be dissociated, 25, 58 and different cell lines have shown nonparallel apoA-I-mediated cholesterol and phospholipid efflux, 59 suggesting distinctly regulated ABCA1-dependent cholesterol and phospholipid efflux pathways. Studies from our group suggest that this lipid efflux pathway is in part regulated by stearyol CoA desaturase (SCD), a rate-limiting enzyme in the cellular synthesis of monounsaturated fatty acids from saturated fatty acids. 58 Coexpression of ABCA1 and SCD reduced ABCA1-mediated cholesterol efflux but not phospholipid efflux to apoA-I, whereas SCD expression increased cholesterol efflux to HDL 2 , 58 a process independent of ABCA1. 25 SCD expression did not alter ABCA1 mRNA or protein levels, 58 excluding the potential effect of increased unsaturated fatty acid levels in SCD expressing cells as a cause of reduced ABCA1 protein levels. 53, 54 Confocal microscopy showed that SCD overexpression led to a decrease in Triton X-100 -resistant membrane liquid-ordered domains and an increase in membrane liquid domains. 58 Because cellular free cholesterol, cholesterol ester, and phospholipid content did not change in SCD-overexpressing cells, a likely explanation for SCDinduced reduction of ABCA1-mediated cholesterol efflux would be that less cholesterol is available for ABCA1-facilitated efflux in the expanded Triton X-100 -soluble domains containing ABCA1. These data are consistent with coordinated cholesterol and phospholipid efflux by ABCA1 and with the results of kinetic studies of apoA-I-mediated lipid efflux from macrophages, showing that cholesterol and phospholipid efflux are parallel in cells with upregulated ABCA1 expression, 60, 61 as reviewed elsewhere in this series. However, they are in contrast with the 2-step model proposed for ABCA1-mediated lipid efflux, which suggests an initial formation of apoA-I/phospholipid complexes promoted by ABCA1 followed by cholesterol efflux from a membrane domain in an ABCA1-independent fashion. 25, 62 In addition to ABCA1, several other ABC transporters have been shown to primarily facilitate lipid exo-transport. ABCB4 (human MDR3 and mouse MDR2) is localized on the canalicular membranes of hepatocytes and plays an essential role in phosphatidylcholine secretion into bile. 63 Recently, ABCG5 and ABCG8, mutated genes in sitosterolemia, 64 have been shown to form functional heterodimers promoting plant sterol and cholesterol secretion into bile and possibly intestinal lumen. 65, 66 ABCA4 (ABCR), a close relative of ABCA1 and the mutant gene in Stargardt's disease, 67 is specifically expressed in retina and proposed to transport N-retinylidenephosphatidylethanolamine, a product generated during the visual cycle. 68 ABCA1 is distinct from other lipid ABC transporters in that it promotes both phospholipid and cholesterol efflux. Given the high specificity of lipid substrates for other ABC transporters and the above-described evidence supporting the coordinated simultaneous lipid release by ABCA1, we suggest that ABCA1-mediated cholesterol and phospholipid efflux may reflect entirely a substrate specificity, that is, ABCA1 specifically transports both phospholipid and cholesterol as substrates across membranes; the availability of different lipids in the vicinity of ABCA1 may result in a modification of the ratio of cholesterol/phospholipid undergoing efflux (Figure 2 ).
Conclusion
ApoA-I binds specifically to ABCA1, likely involving a direct molecular interaction. Binding of apoA-I to ABCA1 promotes cellular cholesterol and phospholipid efflux, probably as a result of a coordinated specific transmembrane transport of both lipids by ABCA1. ABCA1 expression is highly regulated, both on transcriptional and posttranscriptional levels. The interaction of apoA-I with ABCA1 modulates both forms of regulation. Thus, cholesterol efflux Figure 2 . ABCA1-mediated phospholipid and cholesterol efflux to apoA-I and its regulation. ABCA1 functions primarily at cell surface directly promoting phospholipid and cholesterol efflux to apoA-I (A). The ratio of cholesterol/phospholipids efflux may be modulated by local membrane changes in the ratio of these lipids, which determine the availability of the lipids to the transporter. For example, SCD expression increases membrane mono-unsaturated fatty acids at the expense of saturated fatty acid and decreases the cholesterol pool available for ABCA1-mediated efflux but has no effect on the phospholipid pool (B).
promoted by ABCA1 leads to decreased activation of LXR/ RXR by oxysterols and ultimately decreases ABCA1 transcription and protein levels. In contrast, apoA-I and apoE have a positive effect on ABCA1 protein expression, and this is likely to be important in hepatocytes and macrophage foam cells. Intense interest has recently centered on the possibility that increasing macrophage cholesterol efflux could represent a novel approach to treatment of atherosclerosis. LXR/RXR target a battery of genes mediating cholesterol efflux, transport, and excretion, and LXR activators are antiatherogenic. 14 However, LXR/RXR also increases transcription of SREBP1c and its target genes, causing fatty liver and hypertriglyceridemia. 69, 70 Therefore, calpain protease inhibitors, 71 or small molecules that modulate the local interaction of ABCA1 with calpain protease at the plasma membrane, might be an alternative way to upregulate ABCA1 protein and function. Low-affinity small peptides that mimic the binding of lipid-free apolipoproteins to ABCA1 could stabilize the transporter while allowing lipid efflux to apoA-I or apoE.
